Brokerage firm Leerink Partners reiterated an Outperform rating on Nevro Corp. (NVRO)'s stock and raised its price target from $60.00 to to $68.00
For the third quarter 2015, Nevro posted revenue of $15.4 million and a net loss (excluding non-recurring items) of ($0.70) per diluted share, topping the Capital IQ Consensus estimate of ($0.75) loss per share on revenues of $12.45 million for the period
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.
Investment analysts at Morgan Stanley boosted their price target on Alkermes plc (ALKS) shares from $75.00 to to $82.00, while maintaining an Overweight rating.
Alkermes recently reported third quarter 2015 revenues of $152.7 million and a non-GAAP net loss of ($26.2) million or ($0.18) per diluted share for the period
Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Investment bank and asset management firm Piper Jaffray increased its price target from $53.00 to $64.00 and maintained an Overweight rating on shares of Microsoft Corporation (MSFT)
Microsoft delivered first quarter fiscal 2016 revenue of $20.4 billion and non-GAAP net income of $5.4 billion or $0.67 per share
Microsoft a technology company, develops, licenses, and supports software products, services, and devices worldwide.
Diamondback Energy, Inc. (FANG)'s stock had its price target increased to $80.00 from $75.00 by analysts at Stephens
Diamondback Energy posted third quarter adjusted net income of $26.2 million, or $0.40 per share, up from $25.2 million in the previoues quarter.
Diamondback is an independent oil and natural gas Company
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer